New therapies are emerging across the pharmaceutical landscape, due to a convergence of scientific discoveries and innovative technologies. While these therapies bring new hope to patient care, they also add challenges to a complex path to market.
Unpredictable timelines, high drug attrition rates, and decision-making that is in constant instability are all factors that threaten the ability to bring a therapy to market. Flexibility in development and manufacturing is a key factor in establishing operations that can respond to these variables and changing market conditions while also increasing efficiency.
Small and emerging companies that want to accelerate their biomanufacturing operations and protect their resources must find technologies and solutions to complete their workflow safely and efficiently – from idea to injection.